Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add filters








Language
Year range
1.
Acta Medica Iranica. 2011; 49 (12): 789-794
in English | IMEMR | ID: emr-146510

ABSTRACT

The previous large retrospective studies demonstrated that treatment with Statins reduces both the incidence of prostate cancer by 50% and serum Prostate Specific Antigen [PSA] level up to 40%. However the main problem in those studies was the absence of control groups of men with hypercholesterolemia without Statin treatment. We performed a small prospective controlled clinical trial to assess the influence of the treatment with Atorvastatin on serum PSA in men with hypercholesterolemia referred to our educational and treatment center from October 2007 to March 2008. In this study, among the newly diagnosed males with hypercholesterolemia [LDL > 130 mg/dl], 40 patients with LDL more than 190 mg/dl were selected as a case group and were treated with Atorvastatin [20 mg/day]. Among the same population and in the same period, another 40 patients with LDL between 130 and 190 mg/dl were selected as first control group and were treated only with low fat diet. Another 40 patients with normal serum cholesterol and without any treatment were selected as second control group. The lipid profile and serum PSA level of patients of all groups were tested at the first and third months after the therapy. After completion of data, the mean serum lipids and PSA level were measured in both visits and compared with each other by paired t-test. Also the mean PSA change in two visits between three groups was compared by ANOVA and Tukey HSD test. There was not any significant difference in mean baseline PSA between hypercholesterolemic and normocholesterolemic patients [P=0.547]. In case group, mean PSA and LDL was reduced by 14.1% [P<=0001] and 30% [P=0.0001] respectively by second visit. In first control group, mean PSA was not changed significantly [P=0.337], whereas mean LDL in this group was reduced by 9.6% [P= 0.0001]. Similarly in the second control group mean PSA was not changed significantly [P=0.309] by second visit. In addition, mean change of PSA in case group was compared with first and second control groups that was significantly different [P=0.0001] whereas mean change of PSA between two control groups was not significantly different [P=0.615]. The results of this study showed that: 1] Short term treatment with Atorvastatin can reduce serum PSA level, and 2] This reduction is more likely to be due to direct effect and is not related to lowering serum cholesterol levels. Thus, if results of this study are confirmed by large prospective randomized clinical trials with longer follow up period, it will be possible that Atorvastatin could be used in long term as a safe chemoprophylactic agent against prostate cancer in high risk patients


Subject(s)
Humans , Male , Pyrroles , Prostate-Specific Antigen/blood , Hydroxymethylglutaryl-CoA Reductase Inhibitors , Hypercholesterolemia/blood , Hypercholesterolemia/drug therapy , Cholesterol, LDL/blood , Prospective Studies , Triglycerides/blood
2.
Pakistan Journal of Medical Sciences. 2009; 25 (3): 353-358
in English | IMEMR | ID: emr-93985

ABSTRACT

To assess the incidence of complications during percutaneous nephrolithotomy. We studied the files of patients at our urology research center in Rasht, Iran from 2007-2008. One hundred and seventy four patients with symptomatic renal and upper ureteric calculi were selected with the technique of non-probability convenient sampling. Complications of surgery were evaluated and divided into 3 categories: peri-operative, early, and late complications of surgery. Perioperative complications included bleeding, transfusion, extravasation, and injury to adjacent organs. Early complications following surgery included post operative bleeding, post operative transfusion, extravasation, infection, and residual stones. Late complications included injury to adjacent organs. All patients were subjected to PCNL. The data was analyzed on SPSS version 10. Regardless of position, the pelvicaliceal system could be successfully approached in all patients. The mean age of patients was 44.71 +/- 13.16 years. The mean stone size in was 26.64 +/- 14.39 mm. The mean operation time was 95.14 +/- 26.57 minutes. The stone free rate was 85.7%. Peri operative complications included transfusion due to bleeding 5.7%, and extravasation 3.4%. Early complications included transfusion due to bleeding 5.1%, extravasation 2.3%, infection 2.9% and residual calculi 14.3%. Late complications were not seen. No mortality was recorded. The most common stone site was pelvic stone [34.4%]. Stone sites in 45.9% of our patients was in the right kidney while 54.1% was left-sided. PCNL is a valuable treatment option for kidney stones. Potential advantages include less hospital stay with lower cost, lower discomfort and pain, and a lower complication rate. Also PCNL can be applied to many patients with kidney stones. We recommend a subcostal approach and also the use of complete supine PCNL [csPCNL] in decreasing the complications of PCNL


Subject(s)
Humans , Male , Female , Nephrostomy, Percutaneous/methods , Kidney Calculi , Ureteral Calculi , Postoperative Complications , Supine Position , Lithotripsy
3.
Urology Journal. 2008; 5 (1): 37-40
in English | IMEMR | ID: emr-143472

ABSTRACT

Vasectomy is the safest and most reliable method of all the contraception methods, but azoospermia is not achieved immediately by this method. We decided to determine whether irrigation of the vas deferens with sterile water or hypertonic saline solution irrigation during vasectomy would reduce the time needed to obtain azoospermia. A total of 126 fertile men presented for vasectomy were divided in 3 groups. No-scalpel vasectomy was done for all of the participants and irrigation of the vas deferens was carried out during the procedure in 2 groups with either sterile water or hypertonic saline solution [9 g/L sodium chloride solution]. Forty-two participants underwent vasectomy without irrigation. Semen analysis was performed at 4, 8, 12, and 16 weeks after vasectomy. Azoospermia was achieved in all of the men with sterile water after 12 weeks, while at the end of the study [16 weeks] it was achieved in 37 [88.1%] of those with saline solution and in 11 [26.2%] of those without irrigation. There were significant differences in the rates of azoospermia between the participant with sterile water and saline solution at 8 weeks [38.1% versus zero; P < .001], 12 weeks [100% versus 30.9%; P < .001], and 16 weeks [100% versus 88.1%; P = .02]. No pregnancy developed during the follow-up and no complication was reported. Vasal irrigation with sterile water and hypertonic saline solution during vasectomy were effective in removing sperm from the distal vas and increasing the rate at which men achieved azoospermia. Sterile water was a promising option with no complications


Subject(s)
Humans , Male , Vas Deferens , Saline Solution, Hypertonic , Water , Therapeutic Irrigation , Azoospermia , Prospective Studies , Semen Analysis
SELECTION OF CITATIONS
SEARCH DETAIL